Compare INLX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | TPST |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 30.9M |
| IPO Year | 2013 | 2012 |
| Metric | INLX | TPST |
|---|---|---|
| Price | $6.70 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 1.7K | ★ 140.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $11,336.00 | ★ $295,000.00 |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.45 | $1.50 |
| 52 Week High | $14.57 | $12.22 |
| Indicator | INLX | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 44.02 |
| Support Level | N/A | $1.57 |
| Resistance Level | $8.12 | $2.48 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 18.66 | 11.09 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.